ADC Ther­a­peu­tics clears a big hur­dle to­ward its first BLA as piv­otal PhII de­liv­ers up­beat ORR re­sults

ADC Ther­a­peu­tics is get­ting the first piv­otal re­sults for the an­ti­body-drug con­ju­gate pipeline that it has spent 8 years and raised $558 mil­lion to build — and the com­pa­ny says its lead drug has aced the test.

When giv­en to 145 pa­tients with re­lapsed or re­frac­to­ry dif­fuse large B cell lym­phoma (DL­B­CL), lon­cas­tux­imab tesirine in­duced an over­all re­sponse rate of 45.5%, in­clud­ing 20% com­plete re­spons­es. To­geth­er with a large Phase I, this sin­gle-arm, open la­bel Phase II sets ADC Ther­a­peu­tics up nice­ly for a BLA lat­er this year, said CEO Chris Mar­tin.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER